iNovacia AB has developed active compounds as a step towards  treatment of a serious parasitic disease

iNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite Schistosoma have been developed. This parasite infects annually...

Read More

Kancera has filed patent for new active substances against cancer

Kancera reports that the company has registered an international patent application (PCT/EP2011/066250) for a new class of compounds targeting the energy metabolism of cancer cells. This new class of synthetic molecules inhibits the target protein PFKFB3. Inhibition of this...

Read More

Breakthrough for the Kancera ROR Technology Against Incurable Cancer

Kancera has in collaboration with scientists at the Karolinska Institute identified active compounds that effectively kill pancreatic cancer cells. Annually over 100 000 people are diagnosed with pancreatic cancer in Europe and the US. Ratio of survival, five years...

Read More

Interim Report for Kancera AB (publ)

January 1 - June 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's operations are therefore included in the financial statements with...

Read More

Kancera Implements Rights Issue to Develop the Company´s ROR Technology

Kancera is announcing today that the company has raised SEK 7.6m before issue costs in a rights issue. The capital raised will be used to further develop the company's ROR technology to attack solid tumors.

Read More

Kancera’s ROR Technology to Attack Solid Tumors

At a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors that are hard to treat. Kancera has already reported...

Read More

iNovacia Further Develops its Compound Collection

iNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening collection. This is in line with the continuous development...

Read More

Interim Report Q1 2011 for Kancera AB (publ)

January 1 - March 31, 2011 This Interim Report covers the period January 1 - March 31, 2011. As Kancera was established on April 28, 2010, there are no historical comparison figures. All figures relate to the Kancera Group...

Read More

The Annual General Meeting of Kancera AB

The Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011. Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the Board of Directors and the Chief Executive Officer...

Read More

Kancera enters collaboration with investigators at Northwestern University Feinberg School of Medicine, Chicago, USA, to battle aggressive cancer

In line with Kancera's strategy for the development of new therapies towards cancer, the company enters collaboration with Professor Mary Hendrix and her research group at The Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of...

Read More